ImmunoGen Announces Webcast of Presentation and Q&A at the 36th Annual J.P. Morgan Healthcare Conference
January 02 2018 - 8:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that Mark Enyedy, President and CEO, will present
at the upcoming 36th Annual J.P. Morgan Healthcare Conference in
San Francisco. The presentation is scheduled for 8:30am PT (11:30am
ET) on January 10, 2018.
Following the presentation, Mr. Enyedy will be joined by other
members of ImmunoGen’s management team for a question-and-answer
session at 9:00am PT (12:00pm ET).
A webcast of the presentation and question-and-answer session
will be accessible live through the “Investors” section of the
Company’s website, www.immunogen.com; a replay will be available in
the same location for approximately two weeks.
About ImmunoGen, Inc.ImmunoGen is a clinical-stage
biotechnology company that develops targeted cancer therapeutics
using its proprietary ADC technology. The Company’s lead product
candidate, mirvetuximab soravtansine, is in a Phase 3 trial for
FRα-positive platinum-resistant ovarian cancer, and is in a
Phase 1b/2 trial in combination regimens for earlier-stage
disease. ImmunoGen has three additional clinical-stage product
candidates, two of which are being developed in collaboration with
Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in
Roche's marketed product, Kadcyla®, and in programs in development
by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis,
Sanofi and Takeda. More information about the Company can be found
at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including risks related to preclinical
and clinical studies, their timings and results. A review of these
risks can be found in ImmunoGen's Transition Report on Form 10-K
for the fiscal year ended December 31, 2016 and other
reports filed with the Securities and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180102005074/en/
For InvestorsImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorFor MediaImmunoGen,
Inc.Courtney O’Konek,
781-895-0600courtney.okonek@immunogen.comorFTI Consulting
Inc.Robert Stanislaro,
212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024